evolvedMD secures $34 million in Series B funding led by Goldman Sachs Alternatives to expand its integrated behavioral health services in primary care settings.

Information on the Target

evolvedMD, founded in 2017, is a leader in Collaborative Care Management (CoCM), providing integrated behavioral health services within primary care settings. The company employs a unique model that embeds behavioral health providers at more than 200 locations across Arizona, Utah, Florida, New Mexico, and Colorado. These on-site professionals are supported by clinical managers, care coordinators, and psychiatric nurse practitioners, ensuring high-quality mental health services in a convenient and trustworthy environment. evolvedMD has gained significant traction in increasing awareness and adoption of the CoCM model, particularly highlighted by a recent Milliman/Meadows study showcasing high adoption rates in Arizona, their home market.

Industry Overview in the Target’s Specific Country

The behavioral health industry in the United States has faced increasing demand as awareness of mental health issues rises. With mental health challenges affecting millions, there is a pressing need for accessible and effective care solutions. According to analysis by the National Institute of Mental Health, nearly one in five adults in the U.S. live with a mental illness, underscoring the necessity for integrated care models that streamline access to treatment.

With the onset of innovative healthcare models like Collaborative Care, there is a shift towards integrating mental health services into primary care. This integration not only facilitates better patient ou

View Source

Similar Deals

ARCH Venture Partners, GV (Google Ventures) Pelage Pharmaceuticals

2025

Series B Proprietary & Advanced Pharmaceuticals United States of America
EQT Life Sciences, Sanofi Ventures SpliceBio

2025

Series B Bio Therapeutic Drugs United States of America
Accelmed Partners Acclaro Medical

2025

Series B Laser Equipment United States of America
Blue Owl Capital Latigo Biotherapeutics

2025

Series B Bio Therapeutic Drugs United States of America
ABS Capital Partners Greenspace Health

2025

Series B Hospitals, Clinics & Primary Care Services United States of America
Ysios Capital Neurona Therapeutics

2025

Series B Bio Therapeutic Drugs United States of America

Goldman Sachs Alternatives

invested in

evolvedMD

in 2025

in a Series B deal

Disclosed details

Transaction Size: $34M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert